W
W. Appel
Researcher at Lancashire Teaching Hospitals NHS Foundation Trust
Publications - 9
Citations - 703
W. Appel is an academic researcher from Lancashire Teaching Hospitals NHS Foundation Trust. The author has contributed to research in topics: Performance status & Randomized controlled trial. The author has an hindex of 6, co-authored 9 publications receiving 497 citations. Previous affiliations of W. Appel include National Health Service.
Papers
More filters
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Journal ArticleDOI
Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial
Fergus Macbeth,Simon Noble,Jessica Evans,Sheikh Ahmed,David Cohen,Kerenza Hood,Dana Knoyle,S.J. Linnane,Mirella Longo,Barbara Moore,Penella J. Woll,W. Appel,Jeanette Dickson,David Ferry,Caroline Brammer,Gareth Griffiths +15 more
TL;DR: LMWH did not improve overall survival in the patients with lung cancer in this trial, and a significant reduction in VTE is associated with an increase in clinically relevant nonmajor bleeding.
Journal ArticleDOI
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Enriqueta Felip,Andrea Ardizzoni,Tudor Ciuleanu,Manuel Cobo,Konstantin Laktionov,Mária Szilasi,Raffaele Califano,Enric Carcereny,Richard Griffiths,Luis Paz-Ares,Renata Duchnowska,Miriam Alonso Garcia,Dolores Isla,Jacek Jassem,W. Appel,Janusz Milanowski,Jan P. van Meerbeeck,Juergen Wolf,Ang Li,Angelic Acevedo,Sanjay Popat,Sanjay Popat +21 more
TL;DR: In patients with ECOG PS 2, nivolumab had similar tolerability, but outcomes were worse, as expected in this difficult-to-treat, poor prognosis population, with OS outcomes consistent with phase 3 data.
Journal ArticleDOI
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
N. Bayman,W. Appel,Linda Ashcroft,David R Baldwin,Andrew Bates,Liz Darlison,John G. Edwards,Veni Ezhil,David Gilligan,Matthew Hatton,Apurna Jegannathen,Talal Mansy,Michael D Peake,Laura S Pemberton,Robert C. Rintoul,M. Snee,W David J Ryder,Paul Taylor,Corinne Faivre-Finn +18 more
TL;DR: There is no role for the routine use of prophylactic radiotherapy in reducing the incidence of chest wall metastases after a procedure in patients with malignant pleural mesothelioma.
Journal ArticleDOI
CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: The aim was to compare overall survival and toxicity of BD with OD RT using modern conformal RT techniques given concurrently with chemotherapy, and patients’ characteristics were well balanced in both arms.